Table 1.
Baseline demographic and clinical characteristics of patients with NVAF and controls.
| Controls (n = 47) | NVAF Patients (n = 47) | P value | |
|---|---|---|---|
| Age (years) | 59.21 ± 7.43 | 58.78 ± 7.92 | 0.7866 |
| Gender | |||
| Male (n, %) | 25 (53.2) | 24 (51.1) | 0.8364 |
| Female (n, %) | 22 (46.8) | 23 (48.9) | |
| Smoking status | |||
| Current (n, %) | 7 (14.9) | 12 (25.5) | 0.3018 |
| Never (n, %) | 33 (70.2) | 26 (55.3) | |
| Past (n, %) | 7 (14.9) | 9 (19.2) | |
| BMI (kg/m2) | 24.87 ± 4.59 | 26.75 ± 5.51 | 0.0756 |
| Systolic BP (mm Hg) | 119.87 ± 8.96 | 132.39 ± 12.76 | <0.0001 |
| Diastolic BP (mm Hg) | 78.69 ± 9.32 | 86.10 ± 14.72 | 0.0045 |
| Total cholesterol (mg/dl) | 145.62 ± 17.05 | 187.78 ± 36.87 | <0.0001 |
| Low density lipoprotein cholesterol (mg/dl) | 98.65 ± 13.62 | 133.86 ± 33.91 | <0.0001 |
| High density lipoprotein cholesterol (mg/dl) | 44.75 ± 8.90 | 41.34 ± 9.83 | 0.0812 |
| Triglyceride (mg/dl) | 124.06 ± 24.73 | 170.02 ± 55.92 | <0.0001 |
| Comorbidities | |||
| Hypertension (n, %) | — | 8 (17.0) | |
| Dyslipidemia (n, %) | — | 6 (12.8) | |
| Medications | |||
| Antiplatelets (n, %) | — | 25 (53.2) | |
| Anticoagulants (n, %) | — | 18 (38.3) | |
| β-blockers (n, %) | — | 5 (10.6) | |
| ACEIs/ARBs (n, %) | — | 5 (10.6) | |
| Calcium channel blockers (n, %) | — | 4 (8.5) | |
| Digoxin (n, %) | — | 2 (4.3) | |
Values are presented as mean ± SD or as percentage. NVAF, non-valvular atrial fibrillation; BMI, body mass index; BP, blood pressure; ACEIs, angiotensin-converting enzymes inhibitors; ARBs, angiotensin II receptor blockers.